▎WuXiEdited by Kant Content Team

AstraZeneca today announced positive interim results from the Phase III DUO-E trial. The data showed,Compared with patients receiving chemotherapy alone, patients receiving PD-1 inhibitor Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by Imfinzi plus PARP inhibitorLynparza（olaparib，Olaparib) treated advanced or recurrent endometrial cancer patients, achieving improvements in multiple key secondary efficacy endpoints.Among them, the subgroup of patients with proficient mismatch repair (pMMR) benefited the most clinically. Detailed results were presented at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting.

Post-hoc exploratory subgroup analysis based on the mismatch repair (MMR) status of patients' tumors showed,The median duration of response (DoR) for pMMR patients treated with Lynparza and Imfinzi was more than double that of the control group (18.7 months vs 7.6 months).The analysis of other secondary endpoints also showed that pMMR patients receiving the combination treatment of Lynparza and Imfinzi demonstrated better treatment outcomes compared to the control group.Compared with the chemotherapy group, the risk of second progression or death (PFS2) in the combination therapy group was reduced by 32% (not yet reached vs 19.5 months, HR: 0.68, 95% CI: 0.48-0.95).

In the overall trial population, patients receiving the combination of Lynparza and Imfinzi showed improvements in objective response rate (ORR) and duration of response (DoR), along with sustained benefits in secondary endpoints including overall survival (OS), time to first subsequent treatment (TFST), progression-free survival 2 (PFS2), and time to second subsequent treatment (TSST). A detailed summary of efficacy results is as follows:

▲Summary of Efficacy Results from the DUO-E Trial (Image Source: Reference [1])

The safety of the treatment regimen showed controllable and good tolerance in the trial, and the safety profile was consistent with the known conditions of each component drug.

Imfinzi is a monoclonal antibody that binds to the PD-L1 protein, blocking the interaction between PD-L1 and PD-1 and CD80 proteins., counteract the immune escape strategies of tumors, and release the suppression of immune responses.Lynparza is a "first-in-class" PARP inhibitor and also the first synthetic lethal targeted therapy drug., used to target cells/tumors with homologous recombination repair (HRR) deficiency (such as those carryingBRCA1And/OrBRCA2Mutated cells).

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with mismatch repair proficient advanced or recurrent endometrial cancer. Retrieved March 18, 2024 from https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy.html

Disclaimer:WuXi AppTecThe content team focuses on introducing the research progress of the global biopharmaceutical and health industry.This article is for informational exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article.This article is not a recommendation for treatment options.For guidance on treatment options, please visit a正规 hospital.

Copyright Statement:This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media, but unauthorized reproduction by media or institutions in any form to other platforms is strictly prohibited.For reprint authorization, please reply "reprint" on the "WuXi AppTec" WeChat Official Account to obtain the reprint guidelines.